This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human DR3 / TNFRSF25 Protein, Fc Tag
catalog :
TN5-H5258
quantity :
100 ug, 1 mg
price :
290 USD, 1700 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
TN5-H5258
product name :
Human DR3 / TNFRSF25 Protein, Fc Tag
quantity :
100 ug, 1 mg
price :
290 USD, 1700 USD
quantity & price :
$290/100ug,$1700/1mg
target :
DR3 / TNFRSF25
host species :
Human
By Tag :
Fc Tag
Research :
For Research Use Only
Source :
Human DR3, Fc Tag (TN5-H5258) is expressed from human 293 cells (HEK293). It contains AA Gln 25 - Gln 199 (Accession # AAI17190).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human DR3, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Tumor necrosis factor receptor superfamily member 25 (TNFRSF25) is also known as Apo-3, Death receptor 3 (DDR3 or DR3), Apoptosis-inducing receptor AIR, Apoptosis-mediating receptor TRAMP, Lymphocyte-associated receptor of death, Apo-3, which is a member of the TNF-receptor superfamily. TNFRSF25 is a homodimer protein, which can Interact strongly via the death domains with TNFRSF1 and TRADD to activate at least two distinct signaling cascades, apoptosis and NF-kappa-B signaling. TNFRSF25 is receptor for TNFSF12 / APO3L / TWEAK.
References :
(1) Kitson J., et al., 1996, Nature 384:372-375.
(2) Bodmer J.-L., et al., 1997, Immunity 6:79-88.
(3) Marsters S.A., et al., 1996, Curr. Biol. 6:1669-1676.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments